Moderna will require COVID-19 vaccination for all workers in the United States, effective October 1, 2021.

After carefully reviewing the available safety data to date for Moderna COVID-19 Vaccine for cases of myocarditis and/or pericarditis, Moderna has not established a causal association with its vaccine.

A comprehensive assessment of the totality of the available safety data for mRNA-1273 after over 64.5 million doses administered globally does not suggest an association with cerebral venous sinus thrombosis (CVST) or thrombotic events.   Analyses performed using data through March 22, 2021.

Moderna acknowledges receiving a report from the California Department of Public Health (CDPH) that several individuals at one vaccination center in San Diego were treated for possible allergic reactions after vaccination from one lot of Moderna’s COVID-19 Vaccine.

Moderna is committed to working on multiple levels to optimize the impact of mRNA vaccines and therapeutics. Our philosophy on pricing and access reflects a few basic principles: Moderna is committed to developing a broad portfolio of vaccines and therapeutic solutions to address worldwide

The Moderna COVID-19 Vaccine expresses the full-length Spike protein of the SARS-COV-2 virus, allowing for the generation of neutralizing antibody responses to multiple domains of the protein. The full-length Spike protein is 1,273 amino acids long, so while recent variants involve multiple

Moderna, Inc. released a statement on the July 23rd U.S. Patent Trial and Appeal Board (PTAB) ruling.